313673-94-8

Usage

Uses

Used in Pharmaceutical Industry:
7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride is used as an active pharmaceutical ingredient for the development of medications aimed at treating anxiety and mood disorders. Its anxiolytic and antidepressant effects make it a valuable compound in the management of these conditions.
Used in Medication for Anxiety Treatment:
7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride is used as a therapeutic agent for anxiety disorders, providing relief from symptoms associated with excessive worry, fear, and nervousness.
Used in Medication for Mood Disorders:
7-Chloro-2,3,4,5-tetrahydro-1H-benzo[b]azepine hydrochloride is used as a mood stabilizer and antidepressant, helping to alleviate the symptoms of mood disorders such as depression, bipolar disorder, and dysthymia by modulating the levels of mood-regulating neurotransmitters in the brain.

InChI:InChI=1/C10H12ClN/c11-9-4-5-10-8(7-9)3-1-2-6-12-10/h4-5,7,12H,1-3,6H2

Upstream product

• 313673-93-7 7-chloro-1-toluenesulfonyl-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 22344-77-0 7-Chlor-1,3,4,5-tetrahydro-2H-benzazepin-2-on 
• 160129-45-3 7-chloro-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one 
• 193686-76-9 7-chloro-1-(4-methylbenzenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 68253-36-1 1-tetralone oxime 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 

Downstream Products

• 313673-96-0 (7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-2-methyl-4-nitrobenzamide 
• 879999-68-5 7-chloro-1-[2-nitrophenylsulfonyl]-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 879999-67-4 7-chloro-1-(phenylsulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 313673-97-1 (7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-4-amino-2-chlorobenzamide 
• 313673-95-9 (7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)-2-chloro-4-nitrobenzamide 

Relevant academic research and scientific papers

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel

Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction

Histone deacetylase 6 (HDAC6) has become a promising therapeutic target for central nervous system diseases due to its more complex protein structure and biological functions. However, low brain penetration of reported HDAC6 inhibitors limits its clinical application in neurological disorders. Therefore, the benzazepine, a brain-penetrant rigid fragment, was utilized to design a series of selective HDAC6 inhibitors to improve brain bioavailability. Various synthetic strategies were applied to assemble the tetrahydro-benzazepine ring, and 22 compounds were synthesized. Among them, compound 5 showed low nanomolar potency and strong isozyme selectivity for the inhibition of HDAC6 (IC50 = 1.8 nM, 141-fold selectivity over HDAC1) with efficient binding patterns like coordination with the zinc ion and π-π stacking effect. Western blot results showed it could efficiently transport into SH-SY5Y cells and selectively enhance the acetylation level of α-tubulin with a moderate effect on Histone H3. Notably, pharmacokinetic studies demonstrated that compound 5 (brain/plasma ratio of 2.30) had an excellent ability to penetrate the blood-brain barrier of C57 mice. In male rats with transient middle cerebral artery occlusion (MCAO), compound 5 significantly reduced the cerebral infarction from 21.22% to 11.47% and alleviated neurobehavioral deficits in post-ischemic treatment, which provided a strong rationale for pursuing HDAC6-based therapies for ischemic stroke.

Synthesis of tetrahydrobenzazepinesulfonamides and their rearrangement to diarylsulfones

A new class of diarylsulfones, in which tetrahydrobenzazepine comprises one of the aromatic moieties, has been synthesized via the acid-catalyzed rearrangement of several substituted benzazepinesulfonamides. The rearrangement is normally ortho but in at l

Novel design of nonpeptide AVP V2 receptor agonists: Structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template

The discovery of a series of nonpeptide arginine vasopressin V2 receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administr